<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00420290</url>
  </required_header>
  <id_info>
    <org_study_id>060661</org_study_id>
    <nct_id>NCT00420290</nct_id>
  </id_info>
  <brief_title>Inflammation, Proteolysis and IL-1 Beta Receptor Inhibition in Chronic Hemodialysis Patients</brief_title>
  <official_title>Inflammation, Proteolysis and IL-1 Beta Receptor Inhibition in Chronic Hemodialysis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vanderbilt University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chronic hemodialysis (CHD) patients display multiple metabolic abnormalities related to
      advanced uremia. Despite vigorous attempts to prevent these abnormalities and their
      consequences, most CHD patients suffer from a unique form of nutritional derangement, which
      can be termed as &quot;uremic wasting&quot;. Several studies have demonstrated that the presence of
      uremic wasting, especially the degree of loss of muscle mass, sharply increases mortality and
      hospitalization rate in CHD patients.

      Several factors have been thought to be associated with uremic wasting, including hormonal
      derangement, anorexia, physical inactivity, and concurrent illnesses. Chronic inflammation,
      also highly prevalent in these patients, causes muscle catabolism in animal models and
      certain clinical conditions. Epidemiological studies show an association between chronic
      inflammation and uremic wasting in hemodialysis patients indicating a possible causal
      relationship.

      The cause for the activated inflammatory state in CHD patients is believed to be
      multi-factorial. Nevertheless, it is certainly important for the host to limit its biological
      activity by eliciting a stronger anti-inflammatory response, for example through the
      production of naturally occurring receptor antagonist. Interleukin 1 beta, one of the major
      pro-inflammatory cytokines has been shown to be associated with protein catabolism in several
      chronic disease states, including advanced uremia. A balance between interleukin 1 beta
      (agonist) and its naturally occurring receptor antagonist IL-1ra may play a pivotal role in
      controlling the inflammatory response and its consequences in this population.

      The overall goal of this particular grant application is to examine the short-term effects of
      the administration of the recombinant form of IL-1ra on 1) chronic inflammatory state and 2)
      protein homeostasis in chronically inflamed CHD patients.

      We have updated our protocol to perform an interim analysis. The interim analysis will be
      performed after half of the planned study sample has been enrolled (14 subjects; 7 in each
      arm). The interim analysis has been approved by the Data Safety Monitoring Board.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">May 2010</completion_date>
  <primary_completion_date type="Actual">May 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>High Sensitivity C-reactive Protein (hsCRP)</measure>
    <time_frame>month 1</time_frame>
    <description>hsCRP is a sensitive laboratory assay for serum levels of C-reactive protein, which is a biomarker of inflammation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Interleukin-6 (IL-6)</measure>
    <time_frame>month 1</time_frame>
    <description>IL-6 is a sensitive laboratory assay for serum levels of interlukin-6, which is a pro-inflammatory cytokine that is used to evaluate the inflammatory response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Prealbumin</measure>
    <time_frame>month 1</time_frame>
    <description>Prealbumin is a sensitive laboratory assay for serum levels of prealbumin, which is a biomarker of nutrition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Albumin</measure>
    <time_frame>month 1</time_frame>
    <description>Albumin is a sensitive laboratory assay for serum levels of albumin, which is a biomarker of nutrition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lean Body Mass (LBM)</measure>
    <time_frame>month 1</time_frame>
    <description>LBM is a measurement of body composition in terms of lean body mass as determined using Dual Energy X-ray Absorptiometry (DEXA) performed 1 to 2 hours after dialysis.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>End Stage Renal Disease</condition>
  <arm_group>
    <arm_group_label>Kineret</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Interleukin-1 receptor antagonist</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>kineret</intervention_name>
    <description>100 mg administered subcutaneously every other day (3 days a week during hemodialysis) for 4 weeks</description>
    <arm_group_label>Kineret</arm_group_label>
    <other_name>Anakinra</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>100 mg administered subcutaneously every other day (3 days a week during hemodialysis) for 4 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients on CHD for more than 3 months;

          2. Ability to read and sign the consent form;

          3. Have acceptable dialysis adequacy (Kt/V &gt; 1.2);

          4. Use biocompatible hemodialysis membrane;

          5. Have a patent, well functioning, arteriovenous dialysis access;

          6. Signs of chronic inflammation (the average of three consecutive CRP measurements ≥ 5
             mg/L).

        Exclusion Criteria:

          1. Patients with residual renal function &gt; 5 ml/min or urine output &gt; 100 ml/day;

          2. Pregnancy;

          3. Intolerance to the study medication or contraindication to the study medication:
             Hypersensitivity to E. coli-derived proteins, anakinra, or any component of the
             formulation; patients with active infections (including chronic or local infection);

          4. Severe, unstable, active, or chronic inflammatory disease (active infection, active
             connective tissue disorder, active cancer or cancer history in the prior 5 years, HIV,
             liver disease including positive test or history of Hepatitis B or C);

          5. Hospitalization within 1 month prior to the study;

          6. Malfunctioning arterial-venous vascular access [recirculation and/or blood flow &lt; 500
             ml/min for an arterial-venous graft (AVG) or &lt; 400 ml/min for an arterial-venous
             fistula (AVF)];

          7. Patients receiving steroids and/or other immunosuppressive agents;

          8. Life-expectancy less than 6 months;

          9. Age greater than 75 or less than 18 years old;

         10. Hypersensitivity to organic nitrates, isosorbide, or nitroglycerin.

         11. Presence of active infections or a history of pulmonary TB infection with or without
             documented adequate therapy. Subjects with current active TB, or recent close exposure
             to an individual with active TB, are excluded from the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adriana Hung, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Hung AM, Ellis CD, Shintani A, Booker C, Ikizler TA. IL-1β receptor antagonist reduces inflammation in hemodialysis patients. J Am Soc Nephrol. 2011 Mar;22(3):437-42. doi: 10.1681/ASN.2010070760. Epub 2011 Feb 10.</citation>
    <PMID>21310819</PMID>
  </results_reference>
  <verification_date>October 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 10, 2007</study_first_submitted>
  <study_first_submitted_qc>January 10, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 11, 2007</study_first_posted>
  <results_first_submitted>July 11, 2011</results_first_submitted>
  <results_first_submitted_qc>October 10, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 17, 2011</results_first_posted>
  <last_update_submitted>October 10, 2011</last_update_submitted>
  <last_update_submitted_qc>October 10, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 17, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University</investigator_affiliation>
    <investigator_full_name>Adriana Hung</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>inflammation</keyword>
  <keyword>end stage renal disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interleukin 1 Receptor Antagonist Protein</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This study was conducted at the Vanderbilt University Medical Center and Nashville Veterans Affairs Outpatient Dialysis units between January 2008 and May 2010.</recruitment_details>
      <pre_assignment_details>There is a 3-month screening period following enrollment to determine level of inflammation. To be eligible to participate in the intervention phase of the study and be assigned to a group, participants must have three consecutive CRP levels &gt; 5 mg/L. Although 31 subjects were enrolled, only 22 were eligible to be assigned to a group.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Kineret</title>
          <description>100 mg Interleukin-1 receptor antagonist administered subcutaneously every other day (3 days a week during hemodialysis) for 4 weeks</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>100 mg placebo administered subcutaneously every other day (3 days a week during hemodialysis) for 4 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>did not meet inclusion/exclusion</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Kineret</title>
          <description>100 mg Interleukin-1 receptor antagonist administered subcutaneously every other day (3 days a week during hemodialysis) for 4 weeks</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>100 mg placebo administered subcutaneously every other day (3 days a week during hemodialysis) for 4 weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="11"/>
            <count group_id="B2" value="11"/>
            <count group_id="B3" value="22"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45" spread="10.5"/>
                    <measurement group_id="B2" value="50" spread="11.4"/>
                    <measurement group_id="B3" value="47" spread="11.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>High Sensitivity C-reactive Protein (hsCRP)</title>
        <description>hsCRP is a sensitive laboratory assay for serum levels of C-reactive protein, which is a biomarker of inflammation.</description>
        <time_frame>month 1</time_frame>
        <population>The number of participants for analysis was based on those subjects who completed the 4-week study. The analysis was per protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Kineret</title>
            <description>100 mg Interleukin-1 receptor antagonist administered subcutaneously every other day (3 days a week during hemodialysis) for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>100 mg placebo administered subcutaneously every other day (3 days a week during hemodialysis) for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>High Sensitivity C-reactive Protein (hsCRP)</title>
          <description>hsCRP is a sensitive laboratory assay for serum levels of C-reactive protein, which is a biomarker of inflammation.</description>
          <population>The number of participants for analysis was based on those subjects who completed the 4-week study. The analysis was per protocol.</population>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.67" spread="2.87"/>
                    <measurement group_id="O2" value="15.11" spread="10.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Using data from 128 CHD patients, CRP data were highly skewed, and data were log transformed to achieve normality. With 14 pts in each group (total of 28), it was predicted the minimum detectable difference between control and intervention would be 15% (1.22 for control group and 1.00 for the intervention group), with an 80% power and an alpha of 0.05 using t test approach. Thus, planned sample size was 30 to complete the study.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.008</p_value>
            <p_value_desc>0.031 is the upper level of significance</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Interleukin-6 (IL-6)</title>
        <description>IL-6 is a sensitive laboratory assay for serum levels of interlukin-6, which is a pro-inflammatory cytokine that is used to evaluate the inflammatory response.</description>
        <time_frame>month 1</time_frame>
        <population>The number of participants for analysis was based on those subjects who completed the 4-week study. The analysis was per protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Kineret</title>
            <description>100 mg Interleukin-1 receptor antagonist administered subcutaneously every other day (3 days a week during hemodialysis) for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>100 mg placebo administered subcutaneously every other day (3 days a week during hemodialysis) for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Interleukin-6 (IL-6)</title>
          <description>IL-6 is a sensitive laboratory assay for serum levels of interlukin-6, which is a pro-inflammatory cytokine that is used to evaluate the inflammatory response.</description>
          <population>The number of participants for analysis was based on those subjects who completed the 4-week study. The analysis was per protocol.</population>
          <units>pg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.34" spread="3.09"/>
                    <measurement group_id="O2" value="8.14" spread="6.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.03</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Prealbumin</title>
        <description>Prealbumin is a sensitive laboratory assay for serum levels of prealbumin, which is a biomarker of nutrition.</description>
        <time_frame>month 1</time_frame>
        <population>The number of participants for analysis was based on those subjects who completed the 4-week study. The analysis was per protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Kineret</title>
            <description>100 mg Interleukin-1 receptor antagonist administered subcutaneously every other day (3 days a week during hemodialysis) for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>100 mg placebo administered subcutaneously every other day (3 days a week during hemodialysis) for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Prealbumin</title>
          <description>Prealbumin is a sensitive laboratory assay for serum levels of prealbumin, which is a biomarker of nutrition.</description>
          <population>The number of participants for analysis was based on those subjects who completed the 4-week study. The analysis was per protocol.</population>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.43" spread="11.27"/>
                    <measurement group_id="O2" value="33.57" spread="12.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Albumin</title>
        <description>Albumin is a sensitive laboratory assay for serum levels of albumin, which is a biomarker of nutrition.</description>
        <time_frame>month 1</time_frame>
        <population>The number of participants for analysis was based on those subjects who completed the 4-week study. The analysis was per protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Kineret</title>
            <description>100 mg Interleukin-1 receptor antagonist administered subcutaneously every other day (3 days a week during hemodialysis) for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>100 mg placebo administered subcutaneously every other day (3 days a week during hemodialysis) for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Albumin</title>
          <description>Albumin is a sensitive laboratory assay for serum levels of albumin, which is a biomarker of nutrition.</description>
          <population>The number of participants for analysis was based on those subjects who completed the 4-week study. The analysis was per protocol.</population>
          <units>g/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.26" spread="0.40"/>
                    <measurement group_id="O2" value="3.95" spread="0.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Lean Body Mass (LBM)</title>
        <description>LBM is a measurement of body composition in terms of lean body mass as determined using Dual Energy X-ray Absorptiometry (DEXA) performed 1 to 2 hours after dialysis.</description>
        <time_frame>month 1</time_frame>
        <population>The number of participants for analysis was based on those subjects who completed the 4-week study. The analysis was per protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Kineret</title>
            <description>100 mg Interleukin-1 receptor antagonist administered subcutaneously every other day (3 days a week during hemodialysis) for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>100 mg placebo administered subcutaneously every other day (3 days a week during hemodialysis) for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Lean Body Mass (LBM)</title>
          <description>LBM is a measurement of body composition in terms of lean body mass as determined using Dual Energy X-ray Absorptiometry (DEXA) performed 1 to 2 hours after dialysis.</description>
          <population>The number of participants for analysis was based on those subjects who completed the 4-week study. The analysis was per protocol.</population>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.13" spread="8.72"/>
                    <measurement group_id="O2" value="50.38" spread="7.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 month</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Kineret</title>
          <description>100 mg Interleukin-1 receptor antagonist administered subcutaneously every other day (3 days a week during hemodialysis) for 4 weeks</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>100 mg placebo administered subcutaneously every other day (3 days a week during hemodialysis) for 4 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>thrombocytopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>hemodialysis access site infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>asthma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>injection site reaction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>injection site hematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The sample size is small and the intervention is of short duration. Also, the results cannot be generalized to all CHD patients because our inclusion criteria were stringent.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Adriana Hung, MD</name_or_title>
      <organization>Vanderbilt University</organization>
      <email>adriana.hung@vanderbilt.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

